Research programme: eye disorder therapies - Envisia Therapeutics

Drug Profile

Research programme: eye disorder therapies - Envisia Therapeutics

Alternative Names: AR 1105; Controlled-release bevacizumab intravitreal implant - Envisia; Dexamethasone ophthalmic - Envisia Therapeutics; Dexamethasone ophthalmic - Liquidia Technologies; Difluprednate ophthalmic - Envisia Therapeutics; Difluprednate ophthalmic - Liquidia Technologies; ENV 1105; ENV 1305; ENV 705; ENV 905; Extended release anti-VEGF therapy - Envisia; Extended-release bevacizumab - Envisia; Research programme: eye disorder therapies - Liquidia Technologies

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Liquidia Technologies
  • Developer Envisia Therapeutics
  • Class Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Prostaglandins; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Eye-Disorders; Postoperative inflammation; Postoperative pain; Wet age-related macular degeneration

Most Recent Events

  • 05 Oct 2017 Preclinical development is ongoing in Eye disorders in USA
  • 05 Oct 2017 Aerie Pharmaceuticals acquires intellectual property rights related to ENV 1105 from Envisia Therapeutics
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Eye-disorders in USA (Ophthalmic, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top